Advertisement
Screener

ZAI LAB LIMITED (ZLAB) Graph

ZLAB Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue $48.16M; Research and development $61.77M; Selling, general and administrative $72.87M.
  • 2026-03-31: Revenue (m); Cost of revenue $38.31M; Research and development $65.59M; Selling, general and administrative $65.07M.
  • 2025-12-31: Revenue (m); Cost of revenue $62.30M*; Research and development $61.63M*; Selling, general and administrative $73.04M*.
  • 2025-09-30: Revenue (m); Cost of revenue $46.76M; Research and development $47.93M; Selling, general and administrative $70.11M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30(m)$48.16M$61.77M$72.87M-$1.02M-$50.83M
2026-03-31(m)$38.31M$65.59M$65.07M$1.44M-$51.02M
2025-12-31(m)$62.30M*$61.63M*$73.04M*-$2.93M*-$50.37M*
2025-09-30(m)$46.76M$47.93M$70.11M$0.00-$35.96M
2025-06-30(m)$43.00M$50.61M$71.04M$0.00-$40.73M
2025-03-31(m)$38.45M$60.73M$63.42M$0.00-$48.44M
2024-09-30(m)$36.57M$65.98M$67.22M$0.00-$41.67M
2024-06-30(m)$35.15M$61.63M$79.71M$0.00-$80.28M
2024-03-31$87.15M$33.62M$54.65M$69.19M$0.00-$53.47M
2023-09-30$69.23M$25.48M$58.77M$68.55M$0.00-$69.15M
2023-06-30$68.86M$23.76M$76.68M$67.92M$0.00-$120.89M
2023-03-31$62.80M$21.34M$48.47M$62.51M$0.00-$49.14M
2022-09-30(m)$20.04M$99.52M$66.56M$0.00-$161.19M
2022-06-30(m)$17.41M$66.08M$63.40M$0.00-$137.93M
2022-03-31(m)$15.64M$53.85M$56.99M$0.00-$82.39M
2021-12-31$43.96M(m)(m)(m)(m)-$211.82M
2021-09-30$43.10M$12.16M$55.14M$59.00M$0.00-$96.41M
2021-06-30$36.94M$10.87M$142.22M$54.41M$0.00-$163.32M
2021-03-31$20.10M$7.50M$203.85M$35.84M$0.00-$232.91M
2020-12-31$15.09M(m)(m)(m)(m)-$76.55M
2020-09-30$14.65M$4.93M$58.10M$27.87M(m)-$63.74M
2020-06-30$10.99M$2.90M$68.31M$23.76M(m)-$80.63M
2020-03-31$8.22M$2.08M$33.74M$18.71M(m)-$47.99M
2019-12-31(m)(m)(m)(m)$0.00*(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30(m)$86.48M$127.36M$137.94M$418.00K-$101.84M
2025-06-30(m)$81.45M$111.34M$134.46M$0.00-$89.17M
2024-06-30(m)$68.77M$116.27M$148.90M$0.00-$133.75M
2023-06-30$131.66M$45.10M$125.15M$130.43M$0.00-$170.04M
2022-06-30(m)$33.05M$119.94M$120.39M$0.00-$220.33M
2021-06-30$57.04M$18.37M$346.08M$90.25M$0.00-$396.23M
2020-06-30$19.21M$4.98M$102.05M$42.47M$0.00-$128.62M
2019-06-30$3.42M$882.00K$58.93M$29.49M$0.00-$83.27M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30(m)$128.22M$159.27M$204.57M$0.00-$125.13M
2024-09-30(m)$105.34M$182.25M$216.12M$0.00-$175.42M
2023-09-30$200.89M$70.58M$183.92M$198.98M$0.00-$239.19M
2022-09-30(m)$53.09M$219.46M$186.95M$0.00-$381.52M
2021-09-30$100.14M$30.54M$401.22M$149.25M$0.00-$492.65M
2020-09-30$33.86M$9.91M$160.15M$70.35M(m)-$192.36M
2019-09-30$8.34M$2.17M$110.13M$47.19M$0.00-$148.64M
2018-09-30(m)(m)$64.63M$10.60M(m)-$75.72M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31(m)$190.52M$220.90M$277.61M-$2.93M-$175.50M
2024-12-31(m)$147.12M$234.50M$298.74M$0.00-$257.10M
2023-12-31$266.72M$95.82M$265.87M$281.61M$0.00-$334.60M
2022-12-31(m)$74.02M$286.41M$258.97M$0.00-$443.30M
2021-12-31(m)$52.24M$573.31M$218.83M$0.00-$704.50M
2020-12-31$48.96M$16.74M$222.71M$111.31M$0.00-$268.90M
2019-12-31$12.98M$3.75M$142.22M$70.21M$0.00-$195.07M
2018-12-31$129.00K$43.00K$120.28M$21.58M$0.00-$139.07M
2017-12-31(m)(m)$39.34M$12.05M$0.00-$50.38M
2016-12-31(m)(m)$32.15M$6.38M(m)-$37.51M
2015-12-31(m)(m)$13.59M(m)(m)-$18.02M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67